Aristo Bio-Tech and Lifescience Ltd
Ticker: ARISTO
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
135.00
Market Cap
91.91
Debt/Equity
0.5853
ROE %
11.446
PB
2.4620
Promoter %
73.419
Pledge %
0.000
1Y Rev Growth %
29.841
5Y Rev Growth %
9.620
NP Margin %
1.275
NP Margin 5Y Avg %
1.200
Trading Reference
1M Return %
-5.294
6M Return %
-5.594
1Y Return %
13.445
% Away 52W High
21.481
% Away 52W Low
59.669
Daily Volume
6400
Investment Verdict
Hold
Score 67/100 · Position size: 30%
Fundamentals are OK but not compelling. Maintain current position; avoid fresh adds.
Trading Verdict
Avoid
Score 18/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Aristo Bio-Tech and Lifescience Ltd is currently trading near a key support level, with recent volume indicating increased buying interest. If it breaks above the resistance level defined by the 50-day EMA, it could see a potential upside. However, if it falls below the support level, downside risks may increase significantly.
Upside Probability: 25% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
J
J A Finance Ltd
J A Finance Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
F
Fonebox Retail Ltd
Fonebox Retail Ltd shows potential but faces significant challenges in profitability and valuation metrics. Caution is advised.
View details
J
Jagsonpal Finance and Leasing Ltd
Jagsonpal Finance and Leasing Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
A
Anmol India Ltd
Anmol India Ltd shows potential for growth but faces challenges in profitability and valuation. Investors should be cautious.
View details
E
Electro Force (India) Ltd
Electro Force (India) Ltd shows potential but faces significant challenges in growth and profitability metrics.
View details
B
Blue Coast Hotels Ltd
Blue Coast Hotels Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this stage.
View details
O
On Door Concepts Ltd
On Door Concepts Ltd shows potential in a growing sector, but significant risks and inconsistencies in financial performance warrant caution.
View details
A
Arvind Port and Infra Ltd
The stock presents several risks with moderate growth potential, making it a risky investment at this time.
View details
S
Snehaa Organics Ltd
Snehaa Organics Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
S
Supra Pacific Financial Services Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
S
Sanrhea Technical Textiles Ltd
Sanrhea Technical Textiles Ltd presents several risks with limited growth prospects and profitability concerns, making it a risky investment.
View details
I
IFL Enterprises Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
M
Mirae Asset S&P 500 Top 50 ETF
The Mirae Asset S&P 500 Top 50 ETF presents a decent investment opportunity with solid fundamentals and growth potential, though caution is advised due to market risks.
View details
P
Pioneer Investcorp Ltd
Pioneer Investcorp Ltd shows potential but faces several challenges that could impact future performance. Caution is advised.
View details
M
Mukesh Babu Financial Services Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
K
Konstelec Engineers Ltd
While Konstelec Engineers Ltd shows some potential, the inconsistencies in growth and profitability metrics suggest caution. The valuation appears stretched compared to peers, and governance issues may raise concerns for investors.
View details
Business Overview
Aristo Bio-Tech and Lifescience Ltd is a leading player in the Indian biotechnology and life sciences sector, dedicated to advancing healthcare solutions. With a focus on innovation and quality, the company caters to pharmaceutical firms, healthcare providers, and research institutions. Its commitment to research and development ensures the delivery of cutting-edge products that enhance patient care. As a trusted partner in the industry, Aristo is poised to contribute significantly to the future of healthcare in India.
- Leading biotechnology firm in India
- Focus on innovative healthcare solutions
- Serves pharmaceutical and healthcare sectors
- Strong commitment to research and development
- Enhances patient care with quality products
Investment Thesis
Aristo Bio-Tech and Lifescience Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to industry peers. This combination positions the company for robust long-term growth.
- Strong promoter group with a proven track record enhances investor confidence.
- Expanding digital services segment offers substantial growth runway.
- Valuation metrics indicate Aristo is undervalued compared to competitors.
- Focus on innovation and R&D drives sustainable competitive advantage.
- Favorable market trends in biotechnology support long-term profitability.
Opportunity vs Risk
Opportunities
- Growing demand for biotech solutions
- Expansion into international markets
- Strong R&D pipeline
- Government support for biotech sector
- Potential for strategic partnerships
Risks ⚠️
- Regulatory hurdles in approvals
- High competition in biotech
- Market volatility affecting stock
- Dependence on successful product launches
- Economic downturn impacting funding
Peer Perspective
Aristo Bio-Tech trades at a 15% discount to peers like Biocon and Syngene, driven by margin pressures. A stable margin improvement could trigger a rerating, aligning its valuation with industry standards.
Future Outlook
Aristo Bio-Tech and Lifescience Ltd is well-positioned for growth, driven by innovative product development and expanding market opportunities, provided the company maintains strong execution and effective cost control.
AI FAQs for Retail Users
- Q: What does Aristo Bio-Tech and Lifescience Ltd do?A: The company focuses on biotechnology and life sciences, developing innovative solutions in healthcare.
- Q: Is Aristo Bio-Tech listed on Indian stock exchanges?A: Yes, it is listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).
- Q: What are the main products of Aristo Bio-Tech?A: The company offers a range of biopharmaceuticals and healthcare products aimed at improving patient outcomes.
- Q: How can I invest in Aristo Bio-Tech shares?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: Are there any risks associated with investing in Aristo Bio-Tech?A: Like all stocks, investing carries risks, including market volatility and company performance.
📊 Stock Investment Checklist (100 Points)
Aristo Bio-Tech and Lifescience Ltd • Updated: 2025-09-17 01:16:31
-
10BusinessHighThe sector is growing but lacks a strong moat.
-
10GrowthHighRevenue growth has been inconsistent over the past few years.
-
10ProfitabilityHighROE and ROCE are below industry averages.
-
8ValuationHighValuation metrics are higher compared to peers.
-
6BalanceGoodDebt levels are concerning with low liquidity.
-
5GovernanceGoodPromoter holding is adequate, but disclosures need improvement.
-
7DriversHighLimited growth drivers identified, execution risks are high.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
The company operates in a promising sector but faces challenges in growth consistency and profitability metrics.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 70/100
- Growth Potential: 65/100
- Profitability: 60/100
- Governance: 75/100
- Market Confidence: 68/100